Acuta Capital Partners’s Gossamer Bio GOSS Stock Holding History
Bought
Maintained
Sold
Other funds holding GOSS
HA
WAM
NMC
BC
AG
Acuta Capital Partners's GOSS Position: Q4 2022 in Review
Acuta Capital Partners sold out of Gossamer Bio (GOSS) in Q4 2022, closing a stake of 284,500 shares — an estimated $3.41M sold.
Acuta Capital Partners first reported a position in GOSS in Q1 2019 and held it in 5 quarters. The position peaked at $3.41M in Q3 2022. 120 funds tracked by Wall St. Rank hold GOSS as of Q4 2022.
- Acuta Capital Partners reported no remaining Gossamer Bio position as of Q4 2022 after selling out during the quarter.
- Acuta Capital Partners sold 284,500 Gossamer Bio shares in Q4 2022, an estimated $3.41M.
- Acuta Capital Partners first reported a position in Gossamer Bio in Q1 2019 and held it in 5 quarters.
- Acuta Capital Partners's Gossamer Bio position peaked at $3.41M in Q3 2022.
- 120 funds tracked by Wall St. Rank held Gossamer Bio as of Q4 2022.
Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.